Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Table 3 Unadjusted rates of mACR20/50/70 and mHAQ improvement

Outcome, %	Trimmed population			Stratified-matched population
	Rituximab	Anti-TNF	P value	Rituximab	Anti-TNF	P value
	(n = 265)	(n = 737)	P value	(n = 205)	(n = 205)	P value
mACR20	36.6	28.7	0.02	38.1	22.0	0.001
mACR50	21.1	17.4	0.17	21.0	13.7	0.005
mACR70	10.2	8.8	0.46	10.2	7.3	0.29
mHAQ	33.2	24.2	0.004	34.2	23.9	0.02

Anti-TNF anti–tumor necrosis factor, mACR modified American College of Rheumatology criteria, mHAQ modified Health Assessment Questionnaire

ISSN: 1478-6362